Market-Moving News for June 10th
$DSY
$KKR
$SKYE
Containers/Packaging
Consumer Discretionary
Investment Managers
Finance
Get the next $DSY alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/30/2024 | $20.00 | Sector Outperform | Scotiabank | |
| 9/18/2024 | $148.00 | Buy | HSBC Securities | |
| 9/12/2024 | $130.00 | Equal Weight | Wells Fargo | |
| 9/10/2024 | $15.00 | Mkt Outperform | JMP Securities | |
| 8/27/2024 | $153.00 | Buy | Redburn Atlantic | |
| 7/9/2024 | $18.00 | Buy | Craig Hallum | |
| 5/23/2024 | $21.00 | Overweight | Cantor Fitzgerald | |
| 1/4/2024 | $96.00 | Outperform | TD Cowen |
Scotiabank initiated coverage of Skye Bioscience with a rating of Sector Outperform and set a new price target of $20.00
HSBC Securities initiated coverage of KKR with a rating of Buy and set a new price target of $148.00
Wells Fargo initiated coverage of KKR with a rating of Equal Weight and set a new price target of $130.00
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.
KKR & Co. Inc. (NYSE:KKR) today reported its third quarter 2024 results, which have been posted to the Investor Center section of KKR's website at https://ir.kkr.com/events-presentations/. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024827166/en/ A conference call to discuss KKR's financial results will be held today, Thursday, October 24, 2024 at 10:00 a.m. ET. The conference call may be accessed by dialing (877) 407-0312 (U.S. callers) or +1 (201) 389-0899 (non-U.S. callers); a pass code is not required. Additionally, the conference call will be broadcast live over the Internet and may be accessed through the Investor Cen
KKR, a leading global investment firm, today announced that KKR has acquired a portfolio of four Class A industrial warehouses serving the greater Central Florida market, including Orlando and Tampa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241021128092/en/(Photo: Business Wire) The four industrial properties sit at the intersection of Interstate 4 and U.S. Route 27, two vital transportation arteries in southwest Orlando that facilitate access to key demand drivers across Central Florida. The assets, totaling approximately 1.2 million square-feet (SF), are 100% leased to five high-quality tenants, including investment grade
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Reporting)
6-K - Big Tree Cloud Holdings Ltd (0001999297) (Filer)
6-K - Big Tree Cloud Holdings Ltd (0001999297) (Filer)
8-K - Skye Bioscience, Inc. (0001516551) (Filer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
4 - Skye Bioscience, Inc. (0001516551) (Issuer)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G - Skye Bioscience, Inc. (0001516551) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
Instructure shareholders to receive $23.60 per share in cash; Instructure to become a privately held company upon completion of the transactionSALT LAKE CITY, July 25, 2024 /PRNewswire/ -- Instructure Holdings, Inc. (NYSE:INST) ("Instructure"), a leading learning ecosystem, today announced that it has entered into a definitive agreement to be acquired by investment funds managed by KKR, a leading global investment firm, for $23.60 per share in an all-cash transaction valued at an enterprise value of approximately $4.8 billion. The per-share purchase price represents a premium of 16 percent over Instructure's unaffected share price of $20.27 as of May 17, 2024, the last trading day prior to m
All Employees to Become Owners in the CompanyKKR, a leading global investment firm, today announced that investment funds managed by KKR have acquired Marmic Fire & Safety ("Marmic" or the "Company"), a leading provider of regulation-mandated fire equipment inspection, testing and maintenance services, from HGGC. Financial terms were not disclosed.
T-Mobile US, Inc. (NASDAQ:TMUS) signed a deal with KKR & Co. Inc. (NYSE:KKR) to form a joint venture (JV) that will acquire Metronet’s broadband infrastructure, residential fiber operations, and customer base. At closing, T-Mobile plans to invest about $4.9 billion for a 50% stake in the joint venture, acquiring Metronet’s residential fiber operations and customers, and funding the JV. Metronet serves over 2 million homes and businesses across 17 states with its advanced fiber-to-the-home (FTTH) platform. The JV will also acquire Oak Hill Capital’s stake, with Oak Hill re-investing to maintain a minority position and founder John Cinelli retaining a minority stake post-closure. T
SHENZHEN, China, Oct. 31, 2024 /PRNewswire/ -- Big Tree Cloud Holdings Limited ("Big Tree Cloud" or the "Company") (NASDAQ:DSY) (NASDAQ:DSYWW), a company devoted to the development, production, and sales of personal care products and other consumer goods in China, today announced the following changes in directors of the Company and members of the board committees of the Company, each of which took effect on October 31, 2024: (a) the resignation of each of Yifan He, Yanjie ZHU and Fengxin ZHANG (collectively, the "Departing Directors") as an independent director of the Company due to his/her personal reason; (b) the appointment of each of Guo REN, Jiahe LIAO and Munwah WAN (collectively, t
New leadership and reorganization will foster the next chapter of growth and enhance business operations to best support evolving client and CRO partner needs on a global scale. MALVERN, Pa., Oct. 29, 2024 /PRNewswire/ -- Resolian, a leading global bioanalytical and analytical sciences partner supporting drug development and multi-regional clinical trials, today announced several leadership changes as the company expands its global footprint and operational capabilities. Rob Stachlewitz will join Resolian as Chief Executive Officer (CEO), while current CEO Pat Bennett will transition into the newly created role of Chief Business Officer and President of Scientific Affairs. In addition, the
Global Atlantic Financial Group ("Global Atlantic"), a leading insurance provider meeting the retirement and life insurance needs of individuals and institutions, today announced the appointment of Tim Bridgers as Head of Preneed Sales, effective immediately. In this role, Mr. Bridgers will oversee all aspects of Global Atlantic's preneed sales, including agency and funeral home relationships, as well as strategies for marketing, pricing, and product development. He succeeds Kelly Milberger, who is retiring after a distinguished career in the industry. Based in Wilmington, North Carolina, Mr. Bridgers joins Global Atlantic from Live Oak Bank, where he spent a decade in various leadership
Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data shows that nimacimab achieves desired metabolic outcomes without central inhibition and its risk of neuropsychiatric adverse events SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced preliminary data from a diet-induced obesity (DIO) model in mice. Skye's CB1-inhibiting antibody, nimacimab, achieved significant dose-dependent weight
eRESI Capital, LLC ("eRESI" or the "Company"), an innovative mortgage funding platform that offers comprehensive private capital solutions to the residential mortgage market, today announced that it has secured a new investment from insurance accounts managed by KKR, a leading global investment firm. These insurance accounts initially invested in eRESI in 2021. The additional capital is expected to help the Company continue to reach new origination milestones and drive further innovation, excellence, and value for its customers. Founded in 2019, eRESI offers customized products and liquidity solutions to hundreds of mortgage banking partners. With the support of KKR's High-Grade Asset-Base
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that the company's third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. Skye will host a conference call to discuss its results at 1:30 p.m. PT/4:30 p.m. ET. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.
